Ginkgo Bioworks Holdings Inc Stock Price, News & Analysis

Cambrium and Ginkgo Bioworks have successfully completed a partnership focused on optimizing the design of microbes for protein production using generative AI. This collaboration utilized Cambrium's Cloud Protein AI platform alongside Ginkgo's ultra high-throughput screening technology, significantly enhancing protein production processes. Key achievements include the generation of valuable data for strain optimization, identification of new engineering targets, and development of efficient biomanufacturing methods. The project received co-funding from Swiss and German governmental bodies as part of the Eurostars initiative, highlighting its innovative approach to data-driven metabolic engineering.

Ginkgo Bioworks (NYSE: DNA) and Syngenta Seeds announced a research partnership to explore novel traits for future seed development. This collaboration utilizes Ginkgo's advanced protein engineering and high-throughput screening technologies, aimed at enhancing the resilience and health of crops for farmers. The partnership reflects an increasing trend in agriculture towards collaborative innovation, addressing global agricultural challenges through diverse expertise. Ginkgo's Vice President, Magalie Guilhabert, expressed enthusiasm for leveraging their unique technologies to support Syngenta in delivering innovative products to the agricultural sector.

On April 14, 2023, Ginkgo Bioworks (NYSE: DNA) announced a Memorandum of Understanding with the Institut National de la Recherche Biomédicale (INRB) in the Democratic Republic of the Congo (DRC). The partnership aims to enhance biosecurity capabilities in the region's public health institutions. Ginkgo's unit, Concentric by Ginkgo, plans to equip INRB with essential tools, training, and data infrastructure to leverage genomic technologies. This initiative is a key step in building a biosecurity platform that can serve the DRC and its neighbors, addressing the urgent need for effective pathogen monitoring in low-resource areas. Both organizations recognize the importance of collaboration to improve global health security and respond to biological threats effectively.

Ginkgo Bioworks (NYSE: DNA) has announced a partnership with the Wisconsin Alumni Research Foundation (WARF) to develop enhanced GD2 CAR T-cell therapies for solid tumors. The collaboration will leverage Ginkgo's proprietary high-throughput combinatorial CAR discovery platform to create next-generation therapies aimed at addressing T-cell exhaustion. Professors Krishanu Saha and Christian Capitini from the University of Wisconsin-Madison will lead the research efforts. The partnership aims to validate novel CAR designs in high-throughput in vitro and in vivo settings, ultimately improving treatment options for pediatric neuroblastoma. CAR T-cell therapies have shown promise in oncology, predominantly in blood cancers, and this initiative seeks to extend their efficacy to solid tumors, which account for 90% of adult cancers.

Ginkgo Bioworks (NYSE: DNA) will host its annual conference, Ferment, on April 19, 2023, in Boston, MA. This event aims to connect various stakeholders from the synthetic biology ecosystem, including shareholders, customers, and academics. Due to reaching in-person capacity, a video livestream will be made available to the public on the company’s investor relations website. Ginkgo Bioworks is a leader in cell programming, providing services across multiple markets, including food, pharmaceuticals, and biosecurity through its Concentric unit. For more details, visit ginkgobioworks.com.

Sensible Biotechnologies has successfully secured a $4.2 million pre-seed funding round aimed at enhancing its cell-based platform for the efficient manufacturing of high-quality mRNA. The funding, led by BlueYard Capital and supported by notable investors such as Y Combinator and Recode Health Ventures, will facilitate the optimization and scalability of the company's mRNA production capabilities. This initiative is vital as current manufacturing methods struggle with quality and scalability issues. The investment follows a strategic partnership with Ginkgo Bioworks (NYSE: DNA), which will help accelerate the development of Sensible's innovative platform. The funding marks a significant step towards unlocking the potential of mRNA technology for therapeutic applications.

Ginkgo Bioworks (NYSE: DNA) announced the acquisition of StrideBio’s adeno-associated virus (AAV) capsid discovery platform, enhancing its gene therapy capabilities. This transaction includes StrideBio's library of optimized capsids and preclinical data for a genetic heart disease asset. Ginkgo aims to leverage these resources to improve targeting and safety in gene therapies, addressing current limitations in the AAV field. The acquisition solidifies Ginkgo's position as a comprehensive service provider in gene therapy, with expectations to further develop and commercialize advanced gene therapies.

On April 4, 2023, Solvay announced a strategic collaboration with Ginkgo Bioworks (NYSE: DNA) to accelerate the development of sustainable biopolymers, bolstering its position in biotechnology. This multi-year agreement includes the acquisition of a Ginkgo lab in Cambridge, Massachusetts, enhancing Solvay's research capabilities. The partnership aims to leverage synthetic biology to produce environmentally-friendly materials and meet the increasing demand for sustainable solutions. Solvay's CEO highlighted this investment as a pivotal milestone for future growth.

Sensible Biotechnologies has announced a partnership with Ginkgo Bioworks (NYSE: DNA) to develop an in vivo microbial mRNA manufacturing platform. This collaboration aims to address the limitations of conventional in vitro transcription methods, which often struggle with scale and quality. The new method is expected to produce mRNA at a scale of over 100,000 liters, improving the quality and length of mRNA, thereby potentially unlocking new therapeutic applications. Both companies emphasize the need for more efficient mRNA production as the market expands.